「in vitroinvivoin vitroinvivo」の検索結果
153件：61～65件目を表示
-
armaceutical Co., Ltd., hereby announces the commercial launch and distribution of “MIEr for NAVIS” in Japan. MIEr for NAVIS can sharpen images on NAVIS-AZU or NAVIS-CL* by installing Logic and Design...
https://www.senju.co.jp/system/files/content_news/2024-04/ENG_20240423_0.pdf -
产品开发方针 | 研究与开发 | 千寿制药株式会社
人以上未得到必要的治疗。并且报告中还提到白内障、屈光不正（近视、老花眼等）、老年性黄斑变性、青光眼、糖尿病性视网膜病变等是导致全球性视力受损或失明的主要原因。 为创造针对眼部疾病的高价值（First in Class、Best in Class、提升患者便利性等）的产品，今后，我们也将全力推进研究开发活动。我们从“对导致视力受损或失明的眼部疾病的贡献”、“满足未满足的医疗需求*”、“商业化的可能性...
https://www.senju.co.jp/chinese/rd/policy/ -
odel Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of the OptiLight M22 IPL Model in Japan...
https://www.senju.co.jp/system/files/content_news/2023-11/ENG__20231101.pdf -
Business Activities | About Senju | SENJU Pharmaceutical
the world, and a development policy that puts top priority on safety, we have always taken a pioneering path in ophthalmic pharmaceuticals. In the hope of developing even more original new products fo...
http://www.senju.co.jp/english/about/business/ -
-700 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of RET-700 in Japan, effective immediat...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240726_0.pdf